Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (719)	3/9/2000 3:47:00 PM
From: JDN	Read Replies (1) \| Respond to of 783

Dear Tuck: Great news, will BCHE be distributing this drug themselves? JDN

To: tuck who wrote (719)	3/12/2000 1:19:00 PM
From: dalroi	Read Replies (1) \| Respond to of 783

WESTPORT, Mar 10 (Reuters Health) - The Food and Drug Administration has approved BioChem Pharma's Pacis BCG intravesical immunotherapy for treatment of carcinoma in situ of the urinary bladder. Pacis contains live, attenuated Bacillus Calmette-Guerin (BCG) mycobacteria. The recommended course of treatment is a single dose, once per week for 6 weeks, usually administered in the physician's office. Oklahoma City-based UroCor will market Pacis on behalf of BioChem Pharma and expects to launch the product in mid-2000. Michael W. George, president and CEO of UroCor, noted that Pacis is not the first BCG therapeutic on the market, but it is the only one with the original strain. Citing statistics from the American Cancer Society, UroCor said that bladder cancer is the sixth most common cancer in the US, with more than 53,000 people expected to be diagnosed this year. In Thursday trade on the NASDAQ market, shares in UroCor closed up 1-13/16 at 7-5/16. Shares in BioChem Pharma closed up C$2.20 at 36.55 on the Toronto Stock Exchange and up 1-3/8 at 25-1/4 on NASDAQ.